There is a push to diagnose multiple sclerosis (MS) earlier, which can lead to misdiagnosis if the diagnostic criteria aren’t used properly, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.
There is a push to diagnose multiple sclerosis (MS) earlier, which can lead to misdiagnosis if the diagnostic criteria aren’t used properly. As a result, some people are being told they have MS, when they actually don’t, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.
What are some of the diagnostic issues that could make it difficult to make an accurate diagnosis of multiple sclerosis?
Well, first of all, there's a push to diagnose very early so appropriate treatment can be used. Secondly, there's not a good understanding of the 2017 revised McDonald diagnostic criteria, which are the formal diagnostic criteria. They're actually quite useful. I think they're quite easy to understand. We need to be using them on a regular basis.
Thirdly, there is a true misdiagnosis rate. So, the diagnostic criteria are not being applied. And I think this argues for a very robust workup and being aware that people are being told they have MS and they don't, and there's actually some harm being done. So, I think the diagnosis everything starts with diagnosis, and we need to take it very seriously.
How can providers better overcome diagnostic issues to make an earlier diagnosis of multiple sclerosis?
One key is a thorough, robust workup. That means you create a differential diagnosis; you do appropriate bloodwork. For example, anyone who is presenting with possible relapsing ms, I believe you need to check them for IgG [immunoglobulin] to aquaporin-4 in the blood. You need to check them to for IgG to MOG [myelin oligodendrocyte glycoprotein] in the blood to rule out seropositive NMO [neuromyelitis optica] spectrum disorder, and MOGAD—MOG-associated disorders. That should be routinely done.
We need a robust workup. They need MRI imaging, not just of the brain, but I believe of the cervical and the thoracic spinal cord, the other part of the central nervous system, actually imaging down to the conus.
And thirdly, our center routinely lumbar punctures. We look at cerebral spinal fluid. We're looking for CSF [cerebral spinal fluid] oligoclonal band specificity. That's independent of the MRI pattern. It is extraordinarily helpful to assure that you have MS and not another diagnosis. So, I think a thorough workup laboratory evaluation is key.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More